Clinical trials: Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A Phase I Study of HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With ES-SCLC
This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage…
- Trial name
- NCT07892625
- Testing
- HS-20093 for Injection, ZG006, Adebrelimab Injection
- Volunteers
- 338 people
- Sponsor
- Hansoh BioMedical R&D Company
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung…
- Trial name
- EVOKE-SCLC-04 (NCT06801834)
- Testing
- Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only)
- Where
- 219 sites in United States, Argentina and 21 more
- Volunteers
- 695 people
- Sponsor
- Gilead Sciences
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Second-line Immunotherapy for ES-SCLC
At present, the first-line standard treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) is immunotherapy combined with chemotherapy.
- Trial name
- NCT06853678
- Testing
- Adebrelimab, Selinexor, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma
Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )
This study aims to determine safety, tolerability, recommended phase 2 dose (RP2D), and preliminary antitumor activity of 225Ac-SSO110 with standard of care (SoC) therapy in patients with somatostatin receptor 2 expressing…
- Trial name
- SANTANA-225 (NCT06939036)
- Testing
- 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab
- Where
- 7 sites in United States, Australia
- Volunteers
- 2 people
- Sponsor
- Ariceum Therapeutics GmbH
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer
This study aims to investigate the clinical value of small extracellular vesicle (sEV) miRNAs as predictive biomarkers for immunochemotherapy efficacy in extensive-stage small cell lung cancer (ES-SCLC).
- Trial name
- NCT07070011
- Testing
- EC/EP + ICIs
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Shanghai Chest Hospital of Shanghai Jiao Tong University
Small Cell Lung Cancer
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
This is a phase II study. All patients are treatment naive extensive stage small cell lung cancer(ES-SCLC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06769971
- Testing
- Ivonescimab, Cadonilimab, Etoposide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sichuan University
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment.
- Trial name
- CARRY-ON (NCT06663098)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 25 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
ES-SCLC
Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection in combination with Chemotherapy and Sequential Thoracic Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
- Trial name
- NCT07349225
- Testing
- Iparomlimab and Tuvonralimab Injection, Etoposide, Cisplatin
- Volunteers
- 46 people
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
Extensive-stage Small Cell Lung Cancer (ES-SCLC), The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy
Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase
This study is a prospective, randomized, parallel-controlled clinical trial, aiming to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone…
- Trial name
- NCT06961201
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, standard treatment
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
SCLC,Extensive Stage
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)
This is an open-label, single arm, phase 2 trial enrolling patients with untreated Extensive-Stage Small-Cell Lung Cancer (ES SCLC), with a strong translational attitude.
- Trial name
- THOR (NCT05623319)
- Testing
- Pembrolizumab/Olaparib
- Where
- 12 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Small Cell Lung Cancer
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is a single arm, multi-center, open label phase Ib/II study of SC0245 and Irinotecan combination therapy in subjects with extensive-stage small cell lung cancer (ES-SCLC) as a second therapy.
- Trial name
- NCT05731518
- Testing
- SC0245, Irinotecan
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have…
- Trial name
- NCT05765825
- Testing
- serplulimab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 61 people
- Sponsor
- Sichuan University